This study is testing a new medicine, **Sofetabart Mipitecan (Sofe-M)**, for women with ovarian, peritoneal, or fallopian tube cancer. It's in three parts: Part A is for those whose cancer didn't respond well to regular platinum chemotherapy, while Parts B and C are for those whose cancer did respond well. The aim is to see if Sofe-M works better than current treatments and to ensure it's safe.

**Platinum-based chemotherapy** is a common cancer treatment that uses platinum to kill cancer cells. **Platinum-resistant** means the cancer grows even after using this treatment. **Platinum-sensitive** means the cancer stayed controlled for at least six months after treatment.

• **Study Duration:** Depends on how well you respond to the treatment.
• **Participation Requirements:** You'll need to provide a sample of your tumor tissue and meet specific health criteria.
• **Risks and Benefits:** The study aims to find a better treatment, but as with any medicine, there could be risks.